Pain Management

Pharmacists can play an important role in medication management, and prevention strategies for low back pain.

Clinicians generally have 2 options for women who develop endometriosis: surgery or medical therapies. The goal is to address active symptoms, prevent recurrence, and control pain.

Ned Milenkovich, PharmD, JD, is chairman of the health care law practice at Much Shelist PC in Chicago, and former vice chairman of the Illinois State Board of Pharmacy. In this video, he discusses hemp, and why it is drawing increased attention from the pharmacuetical industry.

Opioid abuse has reached epidemic proportions in the united states, with the rising number of opioid-related overdoses and deaths alarming drug manufacturers, health care providers, lawmakers, and patients alike.

What Causes More Opioid Misuse: Higher Doses or Longer Durations?

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The FDA has approved AbbVie's elagolix (Orilissa) product, a drug specifically developed for women with moderate to severe endometriosis pain.

Acute pain is one of the most common complaints that lead Americans to access the health care system, resulting in more than 115 million emergency department visits each year.

The discontinuation of opioid therapy may address the rising death toll caused by drug overdoses while maintaining or potentially improving chronic, non-cancer pain in patients, according to a recent study.

Studies suggest vitamin D deficiency is associated with higher risk of pain, so shouldn’t vitamin D supplementation decrease pain?

Three pain societies have come together to create consensus guidelines for treating both acute and chronic pain with ketamine, an old drug seeing a resurgence.

REMOXY ER is an abuse-deterrent, oral formulation of the widely prescribed opioid medication oxycodone.

The FDA voted against recommendign oxycodone extended-release capsules (REMOXY ER, Pain Therapeutics) for approval for the management of pain severe enough to require long-term, around-the-clock opioid treatment, during a joint meeting of the agency’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC), and the Drug Safety and Risk Management Advisory Committee (DSARM).

Researchers were not able to predict factors that would indicate that pharmacists actually dispense the medication.

Half of people who have diabetes eventually develop diabetic peripheral neuropathy, and the warning signs are sensory symptoms that start in the distant periphery and progressing in a characteristic 'glove and stocking' way.

Health care professionals and consumers are encouraged to report any adverse events related to these products to the FDA’s MedWatch Adverse Event Reporting program.

Opioid use, abuse, and associated deaths have skyrocketed in the United States over the past decade. Since 1999, the number of opioid-related deaths has quadrupled

Erenumab-aooe (Aimovig, Amgen) is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of the molecule that is involved in migraine attacks.

The FDA has approved lofexidine hydrochloride (Lucemyra) for the mitigation of opioid withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.

Originating from damage within nerve cells themselves, neuropathic pain is often complex, with many treatment challenges.

The number of opioids prescribed in the Untied States was approximately 3 times as high in 2015 as it was in 1999.

The FDA approved ZTlido (lidocaine topical system) 1.8% for the treatment of pain associated with post-herpetic neuralgia (PHA), which is caused by shingles.

ZTlido (lidocaine topical system) shows superior adhesion compared with other topical non-opioid pain patches.